Early antiretroviral therapy for patients with acute AIDS-related opportunistic infections: A cost-effectiveness analysis of ACTG A5164

HIV Clinical Trials

Volumn 11, Issue 5, 2010, Pages 248-259

  Sax, Paul E ^a,b   Sloan, Caroline E ^c   Schackman, Bruce R ^d   Grant, Philip M ^e   Rong, Jian ^f   Zolopa, Andrew R ^e,g   Powderly, William ^h   Losina, Elena ^a,i   Freedberg, Kenneth A ^b,c,i  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e STANFORD UNIVERSITY   (United States)

^f FRAMINGHAM HEART STUDY   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY COLLEGE DUBLIN   (Ireland)

ⁱ BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

antiretroviral therapy; cost; cost effectiveness; HIV; opportunistic infection

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPPORTUNISTIC INFECTION; OUTPATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; SURVIVAL; TUBERCULOSIS; UNITED STATES;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HIV; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MALE; MODELS, ECONOMIC; MODELS, IMMUNOLOGICAL; QUALITY-ADJUSTED LIFE YEARS;

EID: 79251615862     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1105-248     Document Type: Article

References (49)

1. Schwarcz S, Hsu L, Dilley JW, Loeb L, Nelson K, Boyd S. Late diagnosis of HIV infection: trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS. J Acquir Immune Defic Syndr. 2006;43(4):491-494.
2. Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-2004. PLoS One. 2009;4(2):e4445.
3. Late HIV testing - 34 states, 1996-2005. MMWR Morb Mortal Wkly Rep. 2009;58(24):661-665.
4. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE. 2009;4(5):e5575.
5. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344(11):824-831. (Pubitemid 32222162)
6. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134(6):440-450.
7. US Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed March 2, 2010.
8. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
9. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(16):1339-1341.
10. *5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008;22(15):2025-2033.
11. Chan PS, Khalid A, Longmore LS, Berg RA, Kosiborod M, Spertus JA. Hospital-wide code rates and mortality before and after implementation of a rapid response team. JAMA. 2008;300(21):2506-2513.
12. Dacey MJ, Mirza ER, Wilcox V, et al. The effect of a rapid response team on major clinical outcome measures in a community hospital. Crit Care Med. 2007;35(9):2076-2082.
13. Multicenter AIDS Cohort Study (MACS) Public Dataset: Release PO4. Springfield, VA: National Technical Information Service; 1995.
14. Mellors JW, Munoz A, Giorgi J V, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946-954.
15. Centers for Medicare and Medicaid Services. Medicare Physician Fee Schedule. 2008. http://www.cms.hhs.gov/PhysicianFeeSched/PFSRVF/list. asp#TopOfPage. Accessed November 2, 2009.
16. Centers for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule. 2008. http://www.cms.hhs.gov/ClinicalLabFeesched/02-clinlab.asp. Accessed November 2, 2009.
17. US Bureau of Labor Statistics. Consumer Price Index (CPI). 2008. http://www.bls.gov/cpi/. Accessed October 21, 2009.
18. American Medical Association. CPT Code/Relative Value Search. 2009. https://catalog.ama-assn.org/Catalog/cpt/cpt-search.jsp?-requestid=570127. Accessed February 24, 2010.
19. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twicedaily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20(5):711-718.
20. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19(7):685-694.
21. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339-354.
22. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359(4):355-365.
23. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49(9):1441-1449.
24. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369(9569):1261-1269.
25. Madruga J V, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1:24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):29-38.
26. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2:24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):39-48.
27. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14):1429-1441.
28. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005;40(4):404-412.
29. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1:24-week results of a phase 2b/3 study in the US and Canada. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, CA. Abstract 104bLB.
30. Reynes J, Arasteh K, Clotet B, et al. TORO: ninety-sixweek virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS. 2007;21(8):533-543.
31. Schackman BR, Gebo KA, Walensky R P, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990-997.
32. University HealthSystem Consortium. CDP online report. https://www.uhc.edu. Accessed November 2, 2009.
33. Bozzette SA, Joyce G, McCaffrey D F, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344(11):817-823.
34. US Bureau of Labor Statistics. Occupational Employment Statistics (OES). 2008. http://data.bls.gov/oes/search.jsp. Accessed June 18, 2009.
35. Johnson D, Friedman R, Ziember D, Lennox JL, Del Rio C. Patients with newly diagnosed HIV who are discharged from a large urban hospital in the United States rarely begin antiretroviral therapy and few achieve an undetectable viral load. Presented at: XVII International AIDS Conference; August 3-8, 2008; Mexico City, Mexico. WEPE0223.
36. Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS. 2008;22(5):601-610.
37. Sax PE, Islam R, Walensky R P, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41(9):1316-1323.
38. Sorensen SV, Frick KD, Wade A, Simko R, Burge R. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and lowdensity lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia. Clin Ther. 2009;31(4):862-879.
39. Lee C P, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009;12(1):80-87.
40. HIV Epidemiology Unit, Georgia Division of Public Health, Georgia Department of Community Health. Georgia HIV/AIDS Surveillance Summary: data through December 31, 2007. 2007. http://health.state.ga.us/epi/hivaids/. Accessed July 8, 2010.
41. Torok M, Yen N, Chau T, et al. Randomised controlled trial of immediate versus deferred antiretroviral therapy in HIV-associated tuberculous meningitis. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009; San Francisco, CA. Abstract H-1224.
42. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19(4):399-406.
43. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005;19(10):1043- 1049.
44. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa. Clin Infect Dis. 2010;50(11):1532-1538.
45. Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr. 2009;51(2):130-134.
46. Sungkanuparph S, Filler SG, Chetchotisakd P, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis. 2009;49(6):931-934.
47. Park WB, Choe PG, Jo JH, et al. Immune reconstitution inflammatory syndrome in the first year after HAART: influence on long-term clinical outcome. AIDS. 2006;20(18):2390-2392.
48. Croda J, Croda MG, Neves A, De Sousa dos Santos S. Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. Crit Care Med. 2009;37(5):1605- 1611.
49. Red Book. Montvale, NJ: Thomson PDR.